DK4076461T3 - Lumateperon til brug ved behandling af skizofreni - Google Patents
Lumateperon til brug ved behandling af skizofreniInfo
- Publication number
- DK4076461T3 DK4076461T3 DK20900863.0T DK20900863T DK4076461T3 DK 4076461 T3 DK4076461 T3 DK 4076461T3 DK 20900863 T DK20900863 T DK 20900863T DK 4076461 T3 DK4076461 T3 DK 4076461T3
- Authority
- DK
- Denmark
- Prior art keywords
- lumateperone
- schizophrenia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950828P | 2019-12-19 | 2019-12-19 | |
| PCT/US2020/066224 WO2021127572A1 (en) | 2019-12-19 | 2020-12-18 | Methods of schizophrenia treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4076461T3 true DK4076461T3 (da) | 2026-02-23 |
Family
ID=76437353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20900863.0T DK4076461T3 (da) | 2019-12-19 | 2020-12-18 | Lumateperon til brug ved behandling af skizofreni |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210186962A1 (da) |
| EP (1) | EP4076461B1 (da) |
| JP (2) | JP7727634B2 (da) |
| DK (1) | DK4076461T3 (da) |
| WO (1) | WO2021127572A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836211B1 (en) | 2012-04-14 | 2019-03-20 | Intra-Cellular Therapies, Inc. | Treatment of PTSD and impulse control disorders |
| CA3094204A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020047407A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12478623B2 (en) | 2019-09-25 | 2025-11-25 | Intra-Cellular Therapies, Inc. | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor |
| BR112022021011A2 (pt) * | 2020-04-17 | 2022-12-27 | Honeybrains Llc | Composições e métodos para tratamento de distúrbios neuropsiquiátricos |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| MXPA01012914A (es) | 1999-06-15 | 2004-04-21 | Bristol Myers Squibb Co | Gama-carbolinas fundidas de heterociclo substituido. |
| CN101796051B (zh) | 2007-03-12 | 2013-11-06 | 细胞内治疗公司 | 与取代的杂环稠合的γ-咔啉的合成 |
| WO2009114181A2 (en) | 2008-03-12 | 2009-09-17 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines solid |
| USRE48839E1 (en) | 2008-05-27 | 2021-12-07 | Intra-Cellular Therapies, Inc | Methods and compositions for sleep disorders and other disorders |
| IL321987A (en) | 2013-12-03 | 2025-09-01 | Intra Cellular Therapies Inc | A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders |
| WO2015154025A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US11331316B2 (en) * | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| AU2018371784B2 (en) * | 2017-11-22 | 2024-10-17 | Sun Pharmaceutical Industries, Inc. | Deuterated analogs of D-serine and uses thereof |
| US11655251B2 (en) * | 2017-11-27 | 2023-05-23 | Egis Gyogyszergyar Zrt. | Method for the production of lumateperone and its salts |
| CA3094204A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20210052472A (ko) | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| WO2020112941A2 (en) * | 2018-11-27 | 2020-06-04 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
-
2020
- 2020-12-18 WO PCT/US2020/066224 patent/WO2021127572A1/en not_active Ceased
- 2020-12-18 US US17/127,867 patent/US20210186962A1/en active Pending
- 2020-12-18 DK DK20900863.0T patent/DK4076461T3/da active
- 2020-12-18 EP EP20900863.0A patent/EP4076461B1/en active Active
- 2020-12-18 JP JP2022537550A patent/JP7727634B2/ja active Active
-
2025
- 2025-08-08 JP JP2025133450A patent/JP2025166121A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021127572A1 (en) | 2021-06-24 |
| JP7727634B2 (ja) | 2025-08-21 |
| US20210186962A1 (en) | 2021-06-24 |
| EP4076461A1 (en) | 2022-10-26 |
| EP4076461B1 (en) | 2026-01-28 |
| EP4076461A4 (en) | 2024-01-03 |
| JP2023507584A (ja) | 2023-02-24 |
| JP2025166121A (ja) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500039I1 (hu) | Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra | |
| DK4076461T3 (da) | Lumateperon til brug ved behandling af skizofreni | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK4010329T3 (da) | Deutererede forbindelser til anvendelse ved behandling af cancer | |
| DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
| DK3578547T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| DK3496739T3 (da) | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| DK4327866T3 (da) | Mirikizumab ved behandling af ulcerøs kolitis | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3806898T3 (da) | Gremlin-1-antagonist til anvendelse i behandling af cancer | |
| DK3240538T3 (da) | Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose | |
| EP3352863A4 (en) | Molybdenum disulfide and related materials for water treatment | |
| DK3970707T3 (da) | Anvendelse af cannabidivarin i behandling af negative symptomer ved skizofreni | |
| EP3434291A4 (en) | COMPOSITION FOR THE TREATMENT OF BELTS | |
| DK3497095T3 (da) | Zinkchelaterende forbindelser til anvendelse ved behandlingen af bakteriel infektion | |
| DK3551189T3 (da) | Alprazolam til anvendelse ved behandling af epilepsi | |
| DK3556383T5 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
| DK3344655T3 (da) | Brug af anti-cd40-antistoffer til behandling af lupus nefritis | |
| DK3432872T3 (da) | Eflornithin til anvendelse til behandling af temozolomid tilbagevendende/refraktær anaplastisk astrocytom | |
| EP3380102A4 (en) | TELOMER EXTENSION AND ANTI-INFLAMMATORY AGENT FOR CELL REGENERATION |